Industry Insights Logo

How to Maximize Partner Support for Referral Capture During a HRSA Audit

SPONSORED CONTENT

A HRSA audit is not a question of if but when. Therefore, it is crucial for covered entities (CEs) to always remain audit-ready. The 340B program has become increasingly complex over the years, prompting service provider partners (partners) in the

Read More »

Trump’s HHS Continues to Oppose Unilateral Drugmaker 340B Rebates in Kalderos Lawsuit

HHS filed a motion for summary judgement against Kalderos, the drug industry vendor behind Eli Lilly’s rebate proposal.
The Trump administration this week continued to oppose drug industry attempts to unilaterally convert 340B discounts to a rebate model, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drugmakers Agree to Take Part in Second Round of IRA’s Medicare Drug Price Talks

A dozen drugmakers have agreed to negotiate prices with the federal government as part of the second round of Medicare drug price talks under the Inflation Reduction Act.
The manufacturers behind 15 drugs selected for the second round of Medicare drug price negotiations under the Inflation Reduction Act [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B INDUSTRY LEADER SPOTLIGHT

Justin Rolling, CaptureRx

Justin Rolling

Q: Where did you grow up?

I grew up in rural southeast Alabama in the small town of Luverne.

Q: Where did you go to college/graduate school?

I attended Troy University for both my Bachelor’s Degree and Master’s Degree and both are in accounting. I also have my CPA license. 

Q: What are your favorites?

Food:  BBQ

Read More »

News Alert

Vermont House Passes Contract Pharmacy Access Bill, While U.S. House Republican Introduces ‘No 340B Savings for Transgender Care Act’

The Vermont House cleared a 340B contract pharmacy access bill by voice vote, sending it to the state Senate.
The Vermont House of Representatives voted this morning to pass a contract pharmacy access bill, the same day that a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Trump Administration Opposes Unilateral Drugmaker 340B Rebates in First Legal Filing on Issue

HHS urged a federal court to dismiss lawsuits from Eli Lilly, Bristol Myers Squibb and Novartis seeking to implement 340B rebate models.
In the Trump administration’s first legal filing on drugmaker 340B rebates, the U.S. Department of Health and Human Services (HHS) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Program Garners National Headlines Over Dark Money Ads, Employer Pharmacy Benefit Plans 

The Associated Press and Wall Street Journal recently published articles that highlighted the 340B program.
The 340B drug pricing program is drawing newfound national media attention following recent articles on a multistate dark money ad [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Maine, Mass. Introduce 340B Contract Pharmacy Access Bills; Mass. Also Introduces Separate Provider Reporting Legislation

Massachusetts state lawmakers recently introduced multiple 340B-related bills, including contract pharmacy access measures and one provider reporting bill.
Lawmakers in Maine and Massachusetts recently introduced bills to prohibit drugmaker 340B contract pharmacy restrictions, while a Bay State legislator [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS Nominee ‘Dr. Oz’ Grilled Over Potential Medicaid Cuts and Position on Medicare Negotiations at Confirmation Hearing 

The Senate Finance Committee pressed Mehmet Oz, known as "Dr. Oz," on whether he would oppose cuts to Medicaid as CMS administrator. Oliver Oz, his son who is marketed as having a leadership role at a 340B services company, sat behind him during the hearing.
Mehmet Oz, President Donald Trump’s (R) nominee to lead the Centers for Medicare & Medicaid Services (CMS), faced persistent questioning—primarily [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Sumitomo, J&J Announce 340B Refunds to Covered Entities

Sumitomo Pharma and Johnson & Johnson announced lists of drugs eligible for refunds.
Two drugmakers recently notified covered entities of adjustments to their 340B drug ceiling prices and resulting refund eligibility. Sumitomo Pharma [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live